Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00880178 · ClinicalTrials.gov registry record

Plaque Inflammation and Dysfunctional HDL in AIM-HIGH

A clinical trial of Cardiovascular Diseases and Heart Diseases, sponsored by University of Washington.

Completed
Registry status
324
Enrollment target
20
Study locations

NCT00880178: Completed study of Cardiovascular Diseases and Heart Diseases, sponsored by University of Washington.

NCT00880178 is a study of Cardiovascular Diseases and Heart Diseases that has completed, run by University of Washington. The registered enrollment target is 324 participants, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00880178, a study of Cardiovascular Diseases and Heart Diseases, has completed, sponsored by University of Washington.

COMPLETED
Registry status
324 participants
Enrollment target
20
Study locations

Study Summary

Coronary heart disease (CHD) is a serious health concern that affects millions of people in the United States. It is usually caused by atherosclerosis-a condition that occurs when fatty material and plaque build up on the walls of the arteries that supply blood and oxygen to the heart, causing the arteries to narrow. As the arteries narrow, blood flow to the heart can slow down or stop, which can cause chest pain, shortness of breath, heart attack, or heart failure. Another component of CHD events involves inflammatory changes that result in structural breakdown of atherosclerotic plaques. Adding niacin to statin medications may be an effective way to block inflammation in the atherosclerotic plaques. This study will examine magnetic resonance imaging (MRI) images and blood samples of participants in the AIM-HIGH study who are taking niacin plus statins or statins alone to determine the effect of these medications on inflammation in atherosclerotic plaques.

Interventions

  • DRUG Simvastatin
  • DRUG Simvastatin and Extended-Release niacin

Study Locations (20)

North Carolina

  • Duke University - Durham
  • Wake Forest University, Geriatrics - Greensboro
  • Wake Forest University, Cardiology - Winston-Salem
  • Wake Forest University, Endocrinology - Winston-Salem

Minnesota

  • University of Minnesota - Minneapolis
  • HealthPartners Riverside Clinic - Minneapolis
  • Mayo Clinic - Rochester

Pennsylvania

  • Philadelphia VA Medical Center - Philadelphia
  • Pennsylvania Cardiology Associates - Philadelphia
  • Cardiology Consultants of Philadelphia - Philadelphia

Texas

  • Baylor College of Medicine - Houston
  • Kelsey Research Foundation - Houston
  • Methodist Hospital - Houston

Alabama

  • Cardiovascular Associates - Birmingham

Arizona

  • Cardiovascular Consultants - Phoenix

California

  • Long Beach VA Medical Center - Long Beach

Delaware

  • Christiana Care Health Services - Newark

Trial Details

FieldValue
Enrollment Target 324 participants
Start Date 2008-05
Est. Completion 2011-09
University of Washington

1,048 total trials

What the finished NCT00880178 record still lists

NCT00880178 is an observational study that tracks outcomes without assigning an intervention. The registered 324 participants enrollment target is mid-sized for trials with a published cap, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower).

The record links to 5 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Simvastatin is the first listed.

NCT00880178 names 20 study sites across 11 states, led by North Carolina, Minnesota, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00880178 about?

NCT00880178 is a clinical study titled "Plaque Inflammation and Dysfunctional HDL in AIM-HIGH". Coronary heart disease (CHD) is a serious health concern that affects millions of people in the United States. It is usually caused by atherosclerosis-a condition that occurs when fatty material and plaque build up on the walls of the arteries that supply blood and oxygen to the heart, causing the a...

What is the current status of trial NCT00880178?

This trial is currently completed. The enrollment target is 324 participants. The study started on 2008-05. Estimated completion is 2011-09.

What conditions does trial NCT00880178 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Heart Diseases, Atherosclerosis, Myocardial Infarction, Coronary Disease.

What interventions are being tested in trial NCT00880178?

The interventions under investigation include: Simvastatin (DRUG), Simvastatin and Extended-Release niacin (DRUG).

Who is sponsoring clinical trial NCT00880178?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00880178 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Delaware, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00880178's enrollment target sits among peer trials

324 119th of 300 higher than 182 of 300 other Cardiovascular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04164173 · 324 participants · NA

    Hyperinflation Respiratory Therapies in Cardiac Surgery Patients

  • NCT04708054 · 324 participants · Phase 2

    Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

  • NCT05261399 · 324 participants · Phase 3

    Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

  • NCT05353322 · 324 participants · NA

    Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00880178, the US trial registry maintained by the National Library of Medicine. NCT00880178 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.